Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

NCT02980263 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Kawasaki Disease

Interventions

DRUG: Canakinumab

Sponsor

Novartis Pharmaceuticals